{"entity":{"id":"turning-point-therapeutics","kind":"company","name":"Turning Point Therapeutics","aka":["Turning Point Therapeutics, Inc.","NASDAQ:TPTX"],"tldr":"Turning Point Therapeutics developed repotrectinib, a pill aimed at lung cancers and other tumours driven by ROS1 or NTRK gene changes. Bristol Myers Squibb bought the company in 2022.","summary":"Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX), of San Diego, was a clinical-stage precision oncology company. Its lead asset, repotrectinib, is a tyrosine kinase inhibitor aimed at the ROS1 and NTRK cancer drivers in non-small cell lung cancer and other advanced solid tumours. Bristol Myers Squibb agreed on 3 June 2022 to buy Turning Point for USD 76 per share in cash, an equity value of USD 4.1 billion, and the merger was completed on 17 August 2022.","asOf":"2026-11-03","links":[{"label":"Bristol Myers Squibb to acquire Turning Point Therapeutics (8-K exhibit 99.1, 3 June 2022)","url":"https://www.sec.gov/Archives/edgar/data/1595893/000119312522166796/d344596dex991.htm"},{"label":"Turning Point investor messages: USD 4.1 billion equity value (Schedule 14D-9C exhibit 99.2)","url":"https://www.sec.gov/Archives/edgar/data/1595893/000119312522166807/d337235dex992.htm"},{"label":"Form 8-K: completion of the merger (17 August 2022)","url":"https://www.sec.gov/Archives/edgar/data/1595893/000114036122029961/brhc10040812_8k.htm"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["ros1","ntrk"],"drugs":["repotrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Completion on 17 August 2022 is from Turning Point's 8-K of that date. No website or founding year is recorded."],"hq":"San Diego, CA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2022,"amountUsd":4100000000,"source":"https://www.sec.gov/Archives/edgar/data/1595893/000119312522166796/d344596dex991.htm","note":"Bristol Myers Squibb's announcement of 3 June 2022, filed as exhibit 99.1 to Turning Point's 8-K: USD 76.00 per share in cash; Turning Point's investor messages filed the same day give an equity value of USD 4.1 billion"}],"acquiredBy":"bms"},"route":"/companies/turning-point-therapeutics/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/"},{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/"}],"drug":[{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}